International Clinical Trial: A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07739186) titled 'A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)' on July 28.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Condition: Non-squamous Non-small Cell Lung Cancer

Intervention: Drug: BL-B01D1 Drug: PD-1/VEGF Bispecific Antibody Drug: Tislelizumab Drug:...